Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OmniAb Inc. (OABIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OABIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.56% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.65 | 52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 |
52 Weeks Range 0.16 - 0.63 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -229.11% | Operating Margin (TTM) -453.64% |
Management Effectiveness
Return on Assets (TTM) -13.18% | Return on Equity (TTM) -21.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 92829276 |
Shares Outstanding - | Shares Floating 92829276 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. (fka Ligand Sciences) spun off its OmniAb antibody discovery platform. Ligand Sciences (founded 1987) evolved over decades, including significant acquisitions and developments in drug discovery technologies. The spin-off as OmniAb focused on antibody discovery.
Core Business Areas
- Antibody Discovery: OmniAb's core business revolves around its transgenic animal platforms for antibody discovery. It licenses these platforms to pharmaceutical and biotech companies for use in developing novel therapeutic antibodies.
- Platform Licensing: The company generates revenue primarily through licensing its OmniAb platforms and related technologies to partners, along with milestone payments and royalties on resulting products.
Leadership and Structure
Matt Foehr is President & CEO. The company has a typical corporate structure with departments overseeing R&D, business development, finance, and legal affairs. Reports to Board of Directors.
Top Products and Market Share
Key Offerings
- OmniAb Platform: A suite of transgenic animals (OmniRat, OmniMouse, OmniFlic, OmniChicken, OmniTaur) engineered to produce fully human antibodies. Market share data is not publicly available. Competitors include Harbour BioMed, Ablexis, and Regeneron (through its VelociGene platform).
Market Dynamics
Industry Overview
The antibody discovery market is experiencing substantial growth, driven by increasing demand for novel antibody-based therapeutics. The market is highly competitive, with various technology platforms and service providers.
Positioning
OmniAb holds a strong position due to its diverse portfolio of transgenic animal platforms and its established track record of successful partnerships. Its competitive advantage lies in the breadth and diversity of its antibody repertoire and the ease of humanization.
Total Addressable Market (TAM)
The global antibody therapeutics market is expected to reach hundreds of billions of dollars. OmniAb is positioned to capture a portion of this TAM through its licensing and royalty-based revenue model.
Upturn SWOT Analysis
Strengths
- Diverse transgenic animal platforms
- Established partnerships with major pharmaceutical companies
- Strong intellectual property portfolio
- Proven track record of antibody discovery
- Experienced management team
Weaknesses
- Reliance on partners for downstream development and commercialization
- Potential competition from newer antibody discovery technologies
- Fluctuations in revenue due to milestone and royalty payments
- Cash burn before revenue is realized
- Relatively smaller market capitalization to competitors
Opportunities
- Expansion into new therapeutic areas
- Development of new transgenic animal platforms
- Strategic acquisitions of complementary technologies
- Increased adoption of antibody-based therapeutics
- Partnering with academic and research institutions
Threats
- Competition from established antibody discovery companies
- Technological advancements that render existing platforms obsolete
- Failure of partner programs to achieve commercial success
- Economic downturns that reduce R&D spending
- Patent challenges
Competitors and Market Share
Key Competitors
- HBM
- REGN
- ABLX
Competitive Landscape
OmniAb competes with established players and emerging technology platforms. Its strengths lie in the breadth of its transgenic animal platforms and its established partnerships, while its weaknesses include its reliance on partners for downstream development and commercialization.
Major Acquisitions
OctoPlus N.V.
- Year: 2012
- Acquisition Price (USD millions): 64
- Strategic Rationale: Acquired to expand drug delivery technologies and capabilities of Ligand Sciences before the OmniAb spinoff.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by new partnerships and successful milestone achievements. Specific financial growth rates are not provided.
Future Projections: Future growth is projected to be driven by the continued expansion of the antibody therapeutics market and the success of partner programs. Analyst estimates are not readily available.
Recent Initiatives: Focus on expanding partnerships, enhancing existing platforms, and investing in new technologies.
Summary
OmniAb is positioned in the growing antibody discovery market with a diverse portfolio of transgenic animal platforms. While it has established partnerships, it is reliant on its partners to realize full commercial potential. Risks include competitive pressure and technological advancement by other companies. The success of the company hinges on continued partner program success and expansion into new therapeutic areas.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
- Analyst Research
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may vary. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2021-09-30 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.